Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    331-201-00079
Previous Study | Return to List | Next Study

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03538691
Recruitment Status : Recruiting
First Posted : May 28, 2018
Last Update Posted : February 15, 2019
Sponsor:
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.

Tracking Information
First Submitted Date  ICMJE April 13, 2018
First Posted Date  ICMJE May 28, 2018
Last Update Posted Date February 15, 2019
Actual Study Start Date  ICMJE July 13, 2018
Estimated Primary Completion Date September 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 24, 2018)
  • Time-to-Relapse in symptoms of Major Depressive Disorder (MDD) [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to week 46 or early termination ]
    Assessed with Montgomery Asberg Depression Rating Scale (MADRS). Scale ranges from 0 to 60 with a higher score indicating worsening symptoms of depression.
  • Time-to-Relapse in symptoms of Major Depressive Disorder (MDD) [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to week 46 or early termination ]
    Assessed with Clinical Global Impression - Severity of Illness (CGI-S) Results. Score ranges from 1 to 7, with a score of 7 being a worse outcome than a score of 1.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03538691 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: May 24, 2018)
  • Change from Phase A baseline in Sheehan Disability Scale (SDS) mean total score at Week 46 [ Time Frame: Up to 46 weeks; from baseline visit at Day 1 to week 46 or early termination ]
    When applicable, the change from phase A baseline in SDS mean total score to the last observation carried forward (week 46). Score ranges from 0 to 10, with a score of 10 being worse than a score of 0.
  • Time-to-Functional Relapse in symptoms of MDD [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to Week 46 or Early Termination ]
    Assessed with Sheehan Disability Scale. Score ranges from 0 to 10, with a score of 10 being worse than a score of 0.
  • Time-to-Relapse in symptoms of MDD [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to Week 46 or Early Termination ]
    Assessed with MADRS criteria. Scale ranges from 0 to 60 with a higher score indicating worsening symptoms of depression.
  • Time-to-Relapse in symptoms of MDD [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to Week 46 or Early Termination ]
    Assessed with CGI-S criteria. Score ranges from 1 to 7, with a score of 7 being a worse outcome than a score of 1.
  • Time-to-relapse in symptoms of MDD [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to Week 46 or Early Termination ]
    Assessed with hospitalization for depression
  • Time-to-Relapse in symptoms of MDD [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to Week 46 or Early Termination ]
    Assessed with lack of efficacy
  • Time-to-Relapse in symptoms of MDD [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to Week 46 or Early Termination ]
    Assessed with active suicidality
  • Percentage of subjects who relapsed based on MADRS criteria [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to Week 46 or Early Termination ]
    Scale ranges from 0 to 60 with a higher score indicating worsening symptoms of depression.
  • Percentage of subjects who relapsed based on CGI-S criteria [ Time Frame: Up to 26 weeks; from baseline visit to Week 46 or Early Termination ]
    Score ranges from 1 to 7, with a score of 7 being a worse outcome than a score of 1.
  • Percentage of subjects who relapse by hospitalization for depression [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to Week 46 or Early Termination ]
  • Percentage of subjects who relapsed by discontinuation due to lack of efficacy or worsening depression [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to Week 46 or Early Termination ]
  • Percentage of subjects who relapsed by active suicidality [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to Week 46 or Early Termination ]
    Based upon MADRS and/or C-SSRS criteria
  • Percentage of subjects maintaining remission [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to Week 46 or Early Termination ]
  • Mean change from randomization in MADRS total score [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to Week 46 or Early Termination ]
  • Mean change from randomization in CGI-S score [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to Week 46 or Early Termination ]
  • Change from randomization in each of the SDS individual item scores (LOCF) [ Time Frame: Up to 26 weeks; from baseline visit at Week 20 to Week 46 or Early Termination ]
    Score ranges from 0 to 10, with a score of 10 being worse than a score of 0.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Official Title  ICMJE A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder
Brief Summary

Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term outcomes remains challenging.

This study will assess the safety, efficacy and tolerability of brexpiprazole as adjunctive therapy to protocol-specific open-label antidepressant therapy.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Major Depressive Disorder
Intervention  ICMJE
  • Drug: Brexpiprazole
    Tablet
    Other Name: OPC-34712
  • Drug: Placebo
    Tablet
  • Drug: Citalopram Hydrobromide
    Tablet
    Other Name: Celexa
  • Drug: Escitalopram
    Tablet
    Other Name: Lexapro
  • Drug: Fluoxetine
    Capsules
    Other Name: Prozac
  • Drug: Paroxetine
    Controlled-release tablets
    Other Name: Paxil CR
  • Drug: Sertraline
    Tablet
    Other Name: Zoloft
  • Drug: Duloxetine
    Delayed-release capsule
    Other Name: Cymbalta
  • Drug: Venlafaxine Extended Release Oral Capsule
    Extended-release capsule
    Other Name: Effexor XR
Study Arms  ICMJE
  • Experimental: Brexpiprazole & Citalopram Hydrobromide
    Brexpiprazole: oral tablet; 2 to 3 mg/day Citalopram hydrobromide: oral tablet; 20 or 40 mg/day
    Interventions:
    • Drug: Brexpiprazole
    • Drug: Citalopram Hydrobromide
  • Placebo Comparator: Placebo & Citalopram Hydrobromide
    Placebo: daily oral tablet Citalopram hydrobromide: oral tablet; 20 or 40 mg/day
    Interventions:
    • Drug: Placebo
    • Drug: Citalopram Hydrobromide
  • Experimental: Brexpiprazole & Escitalopram
    Brexpiprazole: oral tablet; 2 to 3 mg/day Escitalopram: oral tablet; 10 or 20 mg/day
    Interventions:
    • Drug: Brexpiprazole
    • Drug: Escitalopram
  • Placebo Comparator: Placebo & Escitalopram
    Placebo: daily oral tablet Escitalopram: oral tablet; 10 or 20 mg/day
    Interventions:
    • Drug: Placebo
    • Drug: Escitalopram
  • Experimental: Brexpiprazole & Fluoxetine
    Brexpiprazole: oral tablet; 2 to 3 mg/day Fluoxetine: oral capsule; 20 or 40 mg/day
    Interventions:
    • Drug: Brexpiprazole
    • Drug: Fluoxetine
  • Placebo Comparator: Placebo & Fluoxetine
    Placebo: daily oral tablet Fluoxetine: oral capsule; 20 or 40 mg/day
    Interventions:
    • Drug: Placebo
    • Drug: Fluoxetine
  • Experimental: Brexpiprazole & Paroxetine
    Brexpiprazole: oral tablet; 2 to 3 mg/day Paroxetine: oral controlled-release tablet; 37.5 or 50 mg/day
    Interventions:
    • Drug: Brexpiprazole
    • Drug: Paroxetine
  • Placebo Comparator: Placebo & Paroxetine
    Placebo: daily oral tablet Paroxetine: oral controlled-release tablet; 37.5 or 50 mg/day
    Interventions:
    • Drug: Placebo
    • Drug: Paroxetine
  • Experimental: Brexpiprazole & Sertraline
    Brexpiprazole: oral tablet; 2 to 3 mg/day Sertraline: oral tablet; 100, 150 or 200 mg/day
    Interventions:
    • Drug: Brexpiprazole
    • Drug: Sertraline
  • Placebo Comparator: Placebo & Sertraline
    Placebo: daily oral tablet Sertraline: oral tablet; 100, 150 or 200 mg/day
    Interventions:
    • Drug: Placebo
    • Drug: Sertraline
  • Experimental: Brexpiprazole & Duloxetine
    Brexpiprazole: oral tablet; 2 to 3 mg/day Duloxetine: oral delayed-release capsule; 40 or 60 mg/day
    Interventions:
    • Drug: Brexpiprazole
    • Drug: Duloxetine
  • Placebo Comparator: Placebo & Duloxetine
    Placebo: daily oral tablet Duloxetine: oral delayed-release capsule; 40 or 60 mg/day
    Interventions:
    • Drug: Placebo
    • Drug: Duloxetine
  • Experimental: Brexpiprazole & Venlafaxine extended-release (XR)
    Brexpiprazole: oral tablet; 2 to 3 mg/day Venlafaxine XR: daily extended-release capsule; 75, 150, or 225 mg/day
    Interventions:
    • Drug: Brexpiprazole
    • Drug: Venlafaxine Extended Release Oral Capsule
  • Placebo Comparator: Placebo & Venlafaxine extended-release (XR)
    Placebo: daily oral tablet Venlafaxine XR: daily extended-release capsule; 75, 150, or 225 mg/day
    Interventions:
    • Drug: Placebo
    • Drug: Venlafaxine Extended Release Oral Capsule
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 24, 2018)
1450
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 2022
Estimated Primary Completion Date September 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects with both a diagnosis of recurrent major depressive disorder, and in a current major depressive episode of ≥ 8 weeks in duration, as defined by Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) and confirmed by both the Mini International Neuropsychiatric Interview (MINI) and an adequate clinical psychiatric evaluation.
  • Subjects must have reported a history for the current major depressive episode of an inadequate response to 1 or 2 adequate antidepressant treatments, and subjects must currently be taking a protocol-mandated antidepressant treatment at an adequate dose and duration, and most not have reported ≥ 50% improvement. For subjects who are currently on an adequate dose of protocol-mandated antidepressant therapy (ADT), but for an inadequate duration, can use the screening period to achieve adequate duration. At Phase A baseline visit, all subjects must have either 2 or 3 documented inadequate responses to antidepressant treatment in total for the current episode as defined by the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ)
  • Subjects with a Hamilton Rating Scale for Depression (HAM-D17) total score ≥ 18 at the screening visit, and Phase A baseline visits.
  • Subjects willing to discontinue all prohibited psychotropic medications to meet protocol-required washouts prior to and during the trial period.

Exclusion Criteria:

  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving investigational medicinal product (IMP).
  • Sexually active males or females of childbearing potential who do not agree to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days after the last dose of IMP.
  • Subjects who report treatment with adjunctive antipsychotic medication with an antidepressant for a minimum of 3 weeks during the current major depressive episode
  • Subjects who report allergies or an intolerability (lifetime treatment history) to trial-provided ADTs that have not been prescribed to the subject during the current major depressive episode.
  • Subjects who have received ECT for the current major depressive episode
  • Subjects who have had an inadequate response to ECT at any time in the past or who have had a vagus nerve stimulation or deep brain stimulation device implanted at any time for the management of treatment-resistant depression. Subjects who have had transcranial magnetic stimulation during the current major depressive episode.
  • Subjects with a current need for involuntary commitment or who have been hospitalized within 4 weeks of screening for the current major depressive episode.
  • Subjects with a primary DSM-5 diagnosis of:

    1. Schizophrenia Spectrum and Other Psychotic Disorders
    2. Bipolar and Related Disorders
    3. Obsessive Compulsive Disorders
    4. Feeding and Eating Disorders
    5. Neurocognitive Disorders
    6. Panic Disorder
    7. Post-Traumatic Stress Disorder
  • Subjects with a current DSM-5 diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder or intellectual disability.
  • Subjects experiencing hallucinations, delusions, or any psychotic symptomatology in the current major depressive episode
  • Subjects receiving new onset psychotherapy (individual, group, marriage or family therapy) within 42 days of screening or at any time during participation in the trial
  • Subjects who have met DSM-5 criteria for substance use disorder (moderate or severe) within the past 60 days; including alcohol and benzodiazepines, but excluding nicotine
  • Subjects with hypothyroidism or hyperthyroidism (unless condition has been stabilized with medications for at least the past 90 days) and/or an abnormal result for free T4 at screening.
  • Subjects who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders such as any history of myocardial infarction, congestive heart failure, HIV seropositive status/acquired immunodeficiency syndrome, chronic hepatitis B or C.
  • Subjects with diabetes mellitus (IDDM and non-IDDM) are ineligible for the trial unless their condition is stable and well-controlled.
  • Subjects with uncontrolled hypertension (DBP > 95 mmHg) or symptomatic hypotension, or orthostatic hypotension which is defined as a decrease of ≥ 30 mmHg in SBP and/or decrease of ≥ 20 mmHg in DBP after at least 3 minutes standing compared to the previous supine blood pressure OR development of symptoms.
  • Subjects with known ischemic heart disease or history of myocardial infarction-or congestive heart failure (whether controlled or uncontrolled)
  • Subjects with epilepsy or a history of seizures, except for a single seizure episode
  • Subjects with a positive drug screen for cocaine or other drugs of abuse (excluding known prescription stimulants and other medications and marijuana). Detectable levels of alcohol, marijuana, barbiturates, or opiates in the drug screen are not exclusionary if, in the investigator's documented opinion, the subject does not meet DSM-5 criteria for moderate to severe substance use disorder and the positive test does not signal a clinical condition that would impact the safety of the subject or interpretation of the trial results, and participation is agreed to by the medical monitor prior to treatment.
  • Treatment with an MAOI within 14 day prior to the first dose of IMP in Phase A.
  • Use of benzodiazepines and/or hypnotics (including non-benzodiazepine sleep aids) within 7 days prior to first dose of IMP in Phase A.
  • Use of varenicline within 5 days prior to the first dose of IMP in Phase A.
  • Use of oral (or immediate release intramuscular) neuroleptics within 7 days prior or long-acting approved neuroleptics ≤ 1 full cycle plus 1/2 cycle prior to the first dose of IMP in Phase A.
  • Subjects who would be likely to require prohibited concomitant therapy during the trial.
  • Subjects who have been exposed to brexpiprazole in any prior clinical trial or has received commercial brexpiprazole (Rexulti).
  • Subjects with a history of neuroleptic malignant syndrome or serotonin syndrome.
  • Subjects with a history of true allergic response to more than one class of medications
  • Prisoners or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
  • Subjects who participated in any clinical trial within the last 60 days or who participated in more than 2 clinical trials within the past year
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Listed Location Countries  ICMJE Germany,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03538691
Other Study ID Numbers  ICMJE 331-201-00079
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Sponsor  ICMJE Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Otsuka Pharmaceutical Development & Commercialization, Inc.
Verification Date February 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP